Company intelligence
PharmaBoardroom
The ultimate resource for Healthcare & Life Sciences leaders worldwide
About PharmaBoardroom
Pharma Boardroom is the ultimate resource for Healthcare & Life Sciences leaders worldwide. We're your dedicated source for in-depth insights into both local and global markets. Our teams connect with key stakeholders in person, covering every corner of the globe. We go where others don't, conducting face-to-face meetings with industry influencers to deliver unparalleled perspectives on market dynamics. Our commitment to understanding the unique challenges and opportunities in various regions sets us apart. In an ever-evolving healthcare landscape, our extensive network allows you to access firsthand experiences from peers in your local market and beyond. Thanks to our exclusive conversations with industry leaders, we help you access high-level insights. This information loop has proven crucial in shaping successful business strategies in demanding environments. With over a thousand interviews, daily updates, global market news, articles, and a comprehensive database, we are your trusted partner in navigating the regulatory landscape and optimizing business opportunities. Visit our website for more information: https://www.pharmaboardroom.com
Verified activity
Signals from PharmaBoardroom
11 published signals
Legal & Regulatory
PharmaBoardroom reports that childhood myopia now has its first approved pharmacological treatment in Europe, with Santen rolling it out fast.
Reported by PharmaBoardroom
Customers & Market
PharmaBoardroom reports that the treatment for childhood myopia is now available in eight countries across EMEA after launching in Germany one year earlier.
Reported by PharmaBoardroom
Products & Services
PharmaBoardroom reports that Madrigal Pharmaceuticals has one commercial product, Rezdiffra, which is the first treatment ever approved specifically for MASH, a liver disease where more than 20 development programmes failed before it succeeded.
Reported by PharmaBoardroom
Presence & Recognition
PharmaBoardroom reports that Korea's healthcare R&D budget is crossing KRW 1 trillion for the first time, reaching approximately USD 730 million.
Reported by PharmaBoardroom
Presence & Recognition
PharmaBoardroom published exclusive insights on the EU Pharma Legislation reform from health bureaucrat Sandra Gallina, Madrigal Pharmaceuticals Neil Archer, Teva Pharmaceuticals Michal Nitka, and Retina International Avril Daly.
Reported by PharmaBoardroom
Customers & Market
PharmaBoardroom reports that Biocon Biologics is the market leader in the trastuzumab category and the leading insulin biosimilar manufacturer in the US.
Reported by PharmaBoardroom
Customers & Market
PharmaBoardroom reports that Biocon Biologics is the market leader in the trastuzumab category and the leading insulin biosimilar manufacturer in the US.
Reported by PharmaBoardroom
Customers & Market
PharmaBoardroom reports that Biocon Biologics added nine biosimilars to the US market, achieved 25% overall market share, and over 40% of the biosimilar-converted market in ustekinumab, and is preparing pertuzumab, nivolumab, and pembrolizumab biosimilars for the pipeline ahead.
Reported by PharmaBoardroom
Research & Knowledge
PharmaBoardroom published a LinkedIn post discussing Achim Hartig and Roxane Höck discussing the shifting investment landscape in Germany and Europe.
Reported by PharmaBoardroom
Products & Services
PharmaBoardroom reports that Genexine, Inc., a Korean biotech founded by a former Arvinas scientist, is building a biologics-based alternative called bioPROTAC to address the 93% protein unreachability gap.
Reported by PharmaBoardroom
Legal & Regulatory
PharmaBoardroom reports that the world has received its first approved PROTAC therapy, targeting 93% of proteins that cannot be reached by small-molecule PROTAC technology.
Reported by PharmaBoardroom